Montrouge, France

Julien Bouley

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.9

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Montrouge, FR (2018 - 2019)
  • Le Grand Lemps, FR (2021)

Company Filing History:


Years Active: 2018-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Julien Bouley in Immunotherapy

Introduction

Julien Bouley is a notable inventor based in Montrouge, France. He has made significant contributions to the field of immunotherapy, particularly through his innovative research and patents. With a total of 4 patents, Bouley has focused on identifying markers and methods that enhance the efficacy of immunotherapy.

Latest Patents

One of his latest patents is titled "Sialylated fetuin-A as a marker of immunotherapy efficacy." This invention concerns the identification of specific polypeptides and their variants, which can serve as markers for predicting a patient's responsiveness to immunotherapy. Another significant patent involves "Methods for identifying dendritic cell subsets." This invention outlines methods for determining whether a dendritic cell belongs to a tolerogenic or effector subset, as well as assessing a patient's immune response during immunotherapy.

Career Highlights

Julien Bouley is currently associated with Stallergenes, a company known for its work in immunotherapy and allergy treatments. His role at Stallergenes allows him to apply his innovative ideas in a practical setting, contributing to advancements in patient care.

Collaborations

Throughout his career, Bouley has collaborated with esteemed colleagues such as Philippe Moingeon and Emmanuel Nony. These collaborations have further enriched his research and development efforts in the field of immunotherapy.

Conclusion

Julien Bouley's work exemplifies the intersection of innovation and healthcare, particularly in the realm of immunotherapy. His patents and ongoing research continue to pave the way for improved treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…